阿扎胞苷治疗的骨髓增生异常综合征患者循环原始粒细胞的预后价值 - Suppr

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.

作者信息

Kamiya Takahiro, Nakazato Tomonori

机构信息

Department of Hematology, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan.

出版信息

Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3.

DOI:10.1007/s12032-019-1247-3

PMID:30706221

Abstract

摘要

相似文献

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.

Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3.

Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.

Leuk Lymphoma. 2013 Aug;54(8):1786-7. doi: 10.3109/10428194.2012.749406. Epub 2012 Dec 10.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.

Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4.

Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.

Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x.

5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

Leukemia. 2011 Apr;25(4):736-7. doi: 10.1038/leu.2011.6. Epub 2011 Feb 4.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204.

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.

Haematologica. 2013 Feb;98(2):e18-9. doi: 10.3324/haematol.2012.071050. Epub 2012 Sep 14.

本文引用的文献

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Ann Hematol. 2018 Feb;97(2):247-254. doi: 10.1007/s00277-017-3186-4. Epub 2017 Nov 22.

A prognostic score for patients with lower risk myelodysplastic syndrome.

Leukemia. 2008 Mar;22(3):538-43. doi: 10.1038/sj.leu.2405070. Epub 2007 Dec 13.

Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.

Leuk Res. 2008 Jan;32(1):33-7. doi: 10.1016/j.leukres.2007.02.021. Epub 2007 Apr 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献